West Pharmaceutical Services Inc (BSP:W2ST34)
R$ 55.16 0.16 (0.29%) Market Cap: 139.83 Bil Enterprise Value: 138.71 Bil PE Ratio: 48.32 PB Ratio: 8.58 GF Score: 91/100

West Pharmaceutical Services Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 14, 2019 / 10:40PM GMT
Juan Esteban Avendano
BofA Merrill Lynch, Research Division - Associate

We have their CFO and Quintin Lai from IR. So we'll go ahead and get started. Bernard, can you start out by summarizing your first quarter results and the factors that drove performance? That would be good.

Bernard J. Birkett
West Pharmaceutical Services, Inc. - Senior VP, CFO & Treasurer

Okay. So the first quarter was pretty strong which we were pleased to see. We saw growth across our market units which was positive. And we have organic growth of approximately 11% in the quarter and again led by biologics which was again very positive for us to see that market unit continue its rebound and get back to the growth rates that we would expect it to be achieving. And that also drives our high-value product growth rates which is very important from an overall profitability point of view. Generics, again, come in pretty strong. Our pharma division, excluding the Vial2Bag recall impact on revenue, again, was pretty much in line with where we expected it to be for the first quarter. And

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot